The logic of the approach rests on the tight biological relationship between cytomegalovirus and the auditory system. The virus has a pronounced affinity for the structures of the inner ear, where it can damage the cochlea and its hair cells, disrupt the stria vascularis, and inflame the auditory nerve. Damage may be present at birth or may emerge and progress over the first months and years of life, which is why congenital cytomegalovirus accounts for a substantial share of moderate to profound sensorineural hearing loss in children. Because the infection is frequently silent otherwise, a failed hearing screen is often the first and only clue that a newborn carries the virus.

Under a reflexive protocol, that clue triggers a defined sequence of actions rather than an open-ended referral. When an infant fails the initial hearing screen in one or both ears, the hospital initiates a confirmatory test for congenital cytomegalovirus, typically using a saliva or urine specimen analyzed by polymerase chain reaction. Saliva testing, in particular, has been validated as a sensitive first-line method, though care must be taken to collect the sample more than an hour after breastfeeding to avoid false positives from maternal viral shedding in breast milk. A positive saliva result is generally confirmed with urine testing, since urine offers the highest specificity for diagnosing true congenital infection.

The timing of all of this matters enormously, and it is one of the central technical reasons hearing-targeted screening has attracted both enthusiasm and scrutiny. Diagnosis of congenital cytomegalovirus is only reliable within the first three weeks of life. After that window, detection of viral DNA in saliva or urine cannot distinguish an infection acquired in the womb from one acquired during delivery or through breast milk, both of which are common and usually benign. Any screening program that depends on a failed hearing test must therefore move quickly: the hearing screen, the reflexive virologic test, and any confirmatory testing must all be completed before the infant leaves the hospital or within days of discharge if the baby is identified early enough.

Evaluating such a program at a high-volume center provides a distinctive vantage point. Large delivery services process thousands of births annually, which means the logistics of specimen collection, laboratory turnaround, result communication, and follow-up scheduling are tested at real-world scale. A protocol that works smoothly in a small pilot may strain under the throughput of a major hospital, where night and weekend births, transfers to intensive care, staffing variation, and competing nursery priorities can all disrupt the tight sequence of events a reflexive pathway requires. Conversely, high-volume centers also generate enough cases to reveal whether the strategy identifies a clinically meaningful number of infected infants rather than a handful.

The evaluation speaks to a broader, unresolved debate in newborn health policy. Universal screening, in which every newborn is tested for cytomegalovirus regardless of hearing status, maximizes case detection and is favored by many virologists and audiologists. Targeted screening, of which the reflexive hearing-triggered model is the dominant form, tests only a subset of infants and therefore misses infected babies who pass their hearing screens. This is not a trivial omission. A significant proportion of children with congenital cytomegalovirus-related hearing loss pass newborn hearing screening, because the auditory damage may be absent at birth, unilateral, mild enough to escape the screen, or delayed in onset. The virus can also cause other complications, including low birth weight, microcephaly, thrombocytopenia, and, in some cases, long-term neurodevelopmental challenges, that hearing-based selection would never flag.

Defenders of the targeted approach counter that it offers the best available compromise. Testing every infant carries costs in laboratory capacity, specimen handling, parental counseling, and the management of false positives, and the clinical pathway for a positive result remains genuinely uncertain. Antiviral treatment with valganciclovir can improve hearing and developmental outcomes in infants with symptomatic disease, and evidence supports its use in selected cases, but treatment decisions require careful weighing of efficacy against toxicity, including the risk of neutropenia and questions about long-term effects. Identifying an infant through hearing-targeted screening ensures that at least those with an early audible deficit, who are among the most likely to benefit, enter the care pathway within the diagnostic window.

A rigorous assessment of a reflexive program must therefore track several performance dimensions simultaneously. These include the proportion of infants who fail hearing screening and successfully receive virologic testing within twenty-one days, the turnaround time from failed screen to specimen collection and result, the positivity rate among tested infants, the completeness of confirmatory urine testing after an initial saliva positive, and the rate at which identified infants are linked to audiology, ophthalmology, developmental follow-up, and treatment discussions. Attrition is the perennial enemy: every additional step in a chain loses some families, whether because of missed appointments, delayed results, discharge before screening, or incomplete documentation. A high-volume evaluation is well positioned to quantify exactly where in that chain infants fall through.

The findings carry practical implications for hospitals and health systems considering adoption of similar protocols. Successful implementation at scale appears to depend on embedding the cytomegalovirus test into the existing newborn screening workflow by default, so that a failed hearing screen automatically generates a laboratory order rather than depending on individual nurses or physicians to remember and act. Standardized collection kits kept in the nursery, clear protocols for the timing of saliva collection relative to feeding, established laboratory arrangements with rapid polymerase chain reaction turnaround, and scripted counseling materials for parents all reduce the friction that otherwise erodes completion rates. The model also highlights the value of co-locating audiology and infectious disease expertise so that a positive result converts promptly into a coordinated follow-up plan rather than a series of disconnected referrals.

More broadly, the study contributes to the growing international conversation about whether congenital cytomegalovirus belongs among the conditions routinely screened at birth. Professional societies in pediatrics, audiology, and infectious disease continue to weigh the trade-offs, and several regions have moved toward universal testing while others retain targeted models. Whatever policy direction individual health systems take, the central lesson from this high-volume evaluation is that the feasibility of any congenital cytomegalovirus screening strategy rests as much on operational design as on virology. The three-week diagnostic window is unforgiving, the detection technology is mature and reliable, and the treatment evidence is evolving; what determines whether infected infants are actually found and helped is the reliability of the human and logistical machinery connecting a failed hearing test to a laboratory result and a plan of care. Careful, transparent evaluations like this one give hospitals the evidence they need to build that machinery well, and give policymakers a clearer picture of what targeted screening can, and cannot, deliver for the infants it is designed to protect.

Subject of Research: Evaluation of a reflexive, hearing-targeted newborn screening program for congenital cytomegalovirus infection at a high-volume birth center

Article Title: Evaluation of reflexive, hearing-targeted congenital cytomegalovirus screening at a high-volume center

Article References: Thompsen, K., Shah, M., Fishbein, J., Skibley, L., & Mithal, L. B. (2026). Evaluation of reflexive, hearing-targeted congenital cytomegalovirus screening at a high-volume center. Journal of Perinatology. https://doi.org/10.1038/s41372-026-02897-2

Image Credits: AI Generated

DOI: 10.1038/s41372-026-02897-2

Keywords: congenital cytomegalovirus, newborn screening, hearing loss, reflexive testing, sensorineural hearing loss, saliva PCR, valganciclovir, Journal of Perinatology, newborn hearing screening, diagnostic window, high-volume birth center, viral infection